Get the Stockscreener App
0.9627
2.81%
-0.0278
After Hours:
.98
0.0173
+1.80%
Nautilus Biotechnology Inc stock is traded at $0.9627, with a volume of 681.40K.
It is down -2.81% in the last 24 hours and up +9.24% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$0.9905
Open:
$1
24h Volume:
681.40K
Relative Volume:
0.67
Market Cap:
$122.51M
Revenue:
-
Net Income/Loss:
$-57.09M
P/E Ratio:
-2.1313
EPS:
-0.4517
Net Cash Flow:
$-51.43M
1W Performance:
-0.34%
1M Performance:
+9.24%
6M Performance:
-75.38%
1Y Performance:
+17.10%
1-Day Range:
$0.9617
$1.04
1-Week Range:
$0.90
$1.04
52-Week Range:
$0.7752
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.9627 | 122.51M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Nautilus Biotechnology, Inc. SEC Filing (Sep 21, 2026) - Stock Titan
Nautilus Biotechnology details Iterative Mapping for tau proteoform profiling in new video - Traders Union
Nautilus Biotechnology Establishes New At-The-Market Offering - The Globe and Mail
Andreessen Horowitz stake in Nautilus (NASDAQ: NAUT) falls below 5% - Stock Titan
Nautilus Biotechnology May Offer Up To $300 Million Of SecuritiesSEC Filing - TradingView
Nautilus Biotechnology Launches $125 Million ATM Program With TD Cowen; Agent Fee Up to 3% - TradingView
Nautilus Biotechnology (NASDAQ: NAUT) lines up new $300M fundraising capacity - Stock Titan
Nautilus Biotechnology Files $300 Million Shelf Registration - Yahoo Finance
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms - Investing News Network
Nautilus Biotechnology paper on tau proteoform analysis published in Nature Methods - Traders Union
Nautilus found 130 forms of a protein linked to Alzheimer’s. Some appeared in just 0.1% of samples. - Stock Titan
Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceWyckoff Accumulation - dars.gov.et
Nautilus Biotechnology heads to HUPO 2026 to unveil Voyager platform breakthroughs - Traders Union
Andreessen Horowitz sells Nautilus (NAUT) shares around $1 - Stock Titan
Nautilus (NAUT) Q2 2026 Results: EPS Exceeds Its Estimate for the Current Session; Trading Move: The Stock Records a 0.69% Increase at the ClosePre-Announcement Alert - dars.gov.et
Nautilus (NAUT) Market: Finishes 8.30% Down at $0.88 in the Latest Session; Price Levels: the Session Ends Within the Reported Technical BoundariesValue Area Low - vinanet.vn
Nautilus (NAUT) Financial Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Trading Move - vinanet.vn
Nautilus Biotechnology urges new methods to address biological validation challenge in proteomics - Traders Union
Nautilus (NAUT) Watch: Closes 5.82% Higher at $0.90; Technical View: Traders Can Monitor the $0.85-$0.95 Range for the Current SessionSystematic Flow - vinanet.vn
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest - MarketBeat
Nautilus Biotechnology Earnings Call Balances Promise and Risk - TipRanks
NAUT Q2 2026 Earnings: Narrower Loss Surprise Lifts Shares 22%Earnings Deceleration Risk - vinanet.vn
Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A - Stock Titan
Nautilus Biotechnology (NAUT) Slides 3.9% to $0.86, Approaching Key Support LevelLiquidity Order Flow - vinanet.vn
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsMonthly Profile - careplusvn.com
Nautilus Biotechnology Inc (NASDAQ: NAUT) Share Price, NAUT Stock News, NAUT Share Price & Updates - Kalkine
Nautilus Biotechnology (NAUT) Institutional Ownership 2026 - MarketBeat
Nautilus Biotechnology unveils new proteomics approach for dementia studies - Traders Union
Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT) - Seeking Alpha
Nautilus Biotechnology, Inc. Revenue Breakdown – NASDAQ:NAUT - TradingView
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Rises By 74.6% - MarketBeat
Nautilus Biotechnology sets 31 July deadline for Iterative Mapping Grant Program applications - tradersunion.com
Nautilus Biotechnology Inc (NAUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nautilus Biotechnology, Inc. 2026: Revenue $190K, EPS ($0.11) — 10-Q Summary - tradingview.com
Nautilus Biotechnology Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nautilus Biotechnology beats Q2 2026 EPS forecast - Investing.com
Nautilus Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nautilus Biotechnology posts first revenue, Q2 net loss narrows - TradingView
Nautilus Biotechnology (NASDAQ: NAUT) shifts roadmap after Q2 2026 results - Stock Titan
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results - Yahoo Finance
Nautilus Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NAUT|Nautilus Biotechnology Inc|Price:0.977|Chg%:-0.053 - TradingKey
Nautilus Biotechnology reports Q2 2026: $0.2M revenue, $14.5M net loss, $129.2M cash - TradingView
Nautilus Biotechnology Reports $190,000 Revenue in Second Quarter 2026 - Quiver Quantitative
Price to earnings forward of Nautilus Biotechnology, Inc. – NASDAQ:NAUT - TradingView
Nautilus Biotechnology Inc (NAUT) Cash Flow - TradingKey
Nautilus Biotechnology Inc (NAUT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NAUT|Nautilus Biotechnology Inc|Price:1.690|Chg%:-0.080 - TradingKey
Nautilus Biotechnology Inc (NAUT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NAUT|Nautilus Biotechnology Inc|Price:0.980|Chg%:-0.005 - TradingKey
Nautilus Biotechnology Inc (NAUT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):